Piqray (alpelisib)

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

PI3Kα inhibitor

Related drugs:

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 20 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 7 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA exon 9 mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2	alpelisib Resistant: A2 - Guideline alpelisib Resistant : A2
PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2	alpelisib Sensitive: A2 - Guideline alpelisib Sensitive : A2
PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	PIK3CA E542K + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA H1047X	HER2 Negative Breast Cancer	PIK3CA H1047X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA E545X	HER2 Negative Breast Cancer	PIK3CA E545X	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA N345K + PIK3CA N1044K	Breast Cancer	PIK3CA N345K + PIK3CA N1044K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA G106_108del	Breast Cancer	PIK3CA G106_108del	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA R38C	Breast Cancer	PIK3CA R38C	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA Q75E	Breast Cancer	PIK3CA Q75E	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA N345K	Breast Cancer	PIK3CA N345K	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B
PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1	alpelisib Sensitive: C1 - Off-label alpelisib Sensitive : C1
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + alpelisib Sensitive: C2 – Inclusion Criteria trastuzumab + alpelisib Sensitive : C2	trastuzumab + alpelisib Sensitive: C2 – Inclusion Criteria trastuzumab + alpelisib Sensitive : C2
PIK3CA H1047R	Breast Cancer	PIK3CA H1047R	Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3
PTEN mutation	Hormone Receptor Positive Breast Cancer	PTEN mutation	Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3
RNF43 mutation	Colorectal Cancer	RNF43 mutation	Colorectal Cancer	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3	cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials cetuximab + alpelisib + encorafenib Sensitive : C3

Piqray (alpelisib)

Associations
(80)

Associations
(80)

Piqray (alpelisib)

Associations(80)

Associations(80)

Associations
(80)

Associations
(80)